Influenza viruses exhibit a remarkable ability to adapt and evade the host immune response. One way is through antigenic changes that occur on the surface glycoproteins of the virus. The generation of escape variants is a powerful method in elucidating how viruses escape immune detection and in identifying critical residues required for antibody binding. Here, we describe a protocol on how to generate influenza A virus escape variants by utilizing human or murine monoclonal antibodies (mAbs) directed against the viral hemagglutinin (HA). With the use of our technique, we previously characterized critical residues required for the binding of antibodies targeting either the head or stalk of the novel avian H7N9 HA. The protocol can be easily adapted for other virus systems. Analyses of escape variants are important for modeling antigenic drift, determining single nucleotide polymorphisms (SNPs) conferring resistance and virus fitness, and in the designing of vaccines and/or therapeutics.
Introduction
Similar to other RNA viruses, influenza A viruses possess an error-prone polymerase that allows for the generation of a multitude of antigenic variants with each round of replication 1, 2, 3 . The influenza A virus has an astonishing ability to adapt and evade the human immune response via antigenic drift, which is achieved through an accumulation of mutations on the surface glycoproteins that leads to the loss of antibody binding. Antigenic drift of the viral surface glycoproteins, HA and neuraminidase (NA), necessitates the need to reformulate and administer the vaccine annually.
Technological advancements in the isolation and generation of antigen-specific antibodies have yielded a high number of vaccine-induced mAbs 4, 5, 6, 7, 8 . In turn, the characterization of the epitopes of mAbs that broadly neutralize influenza A viruses has greatly aided the development of several universal influenza vaccine candidates 9, 10, 11, 12, 13, 14 . Elucidating the antigenic footprint of a mAb reveals the structural determinants of neutralization and allows for an informed approach towards vaccine design. However, it is neither realistic nor cost-effective for laboratories to structurally characterize extensive panels of mAbs through x-ray crystallography or cryo-electron microscopy in order to map epitopes on the viral antigen 1. Categorizing Antibodies Based on HI and Neutralization Activities 1 . HI assay 1. In a 96-well V-bottom plate, add 25 µL of 1x PBS on columns 2 to 12.
2. Dilute the mAb 7B2 (head-specific), 6F12 (stalk-specific) 23 and an isotype control to 100 µg/mL in 1x PBS and aliquot 50 µL of the diluted antibody preparations into column 1. Also include a no mAb control by adding 50 µL of 1x PBS (Figure 1A) . 3 . Perform 2-fold serial dilutions of the antibodies by transferring 25 µL from column 1 to column 2, and so forth. Discard the last 25 µL from column 12 (Figure 1A) . 8 . Visually read the plates for HI activity. If there is a positive readout for a particular antibody, proceed to step 2.1 to generate escape variants. If the antibody is HI-negative, proceed below to step 1.2 to assess if the antibody has neutralizing activity in a cell culture assay. NOTE: A positive readout of an HI-active mAb is indicated by a dark red RBC pellet in the center of a well (Figure 1B; 7B2 ) that will form a tear drop when the 96-well V-bottom plate is held at a 45° angle. A negative readout will not form a dark red RBC pellet in the well (Figure 1B ; 6F12 and no mAb). The isotype control will also not form a dark red RBC pellet and should look identical to the stalkspecific antibody, 6F12 or the no mAb control sample ( Figure 1B ) 23 . 23. If an antibody has neutralization activity (and no HI activity), proceed to step 2.2.
Microneutralization assay
NOTE: Antibodies that lack in vitro neutralization activity will lack HI activity.
Generation of Escape Mutant Variants
NOTE: Neutralizing antibodies that have or lack HI activity are further analyzed with the specific protocols described below. 4. Incubate for 1 h in a 37 °C incubator (with 5% CO 2 ). Vortex briefly. Inject 200 µL of each mixture into specific-pathogen free (SPF) embryonated chicken eggs. 5. Incubate the eggs at 37 °C (without CO 2 ) for 40-44 h. 6. Sacrifice the virus infected-embryonated eggs by incubating at 4 °C for a minimum of 6 h. 7. Harvest the allantoic fluid from the eggs, as previously described 24, 25 . 8. Perform the hemagglutination assay, as described above 24, 26 . If all of the allantoic fluid preparations do not have hemagglutination titers, repeat from step 2 with antibody dilutions ranging from 0.005 mg/mL to 0.00005 mg/mL. NOTE: A saturating concentration of an HI-positive antibody may neutralize all the virus particles present. Therefore, it may be necessary to decrease the amount of antibody present in the passaging. 9. Confirm the escape variants by performing the HI assay 24 (step 1.1).
NOTE: HI-active antibodies block HA engagement of sialic acid motifs on the target cells. Therefore, a virus in the presence of its cognate antibody loses the ability to agglutinate RBCs (presence of RBC pellet). Theoretically, escape variants of HI-active antibodies can still bind sialic acid motifs even in the presence of its cognate antibody and thus can agglutinate RBCs (no RBC pellet). If the HI of the antibody of interest is still detectable, repeat the protocol from step 2.1.2 with a higher starting concentration of the antibody. Figure 3B ) NOTE: In order to generate escape variants against neutralizing antibodies that lack HI activity, the virus must be passaged in the presence of increasing amounts of antibody. 1. Plate MDCK cells in a 6-well plate at a density of 1 x 10 6 cells/well and incubate for a minimum of 4 h in a 37 °C incubator (with 5% CO 2 ). 2. Dilute the virus stock to 10 6 PFU/mL or the virus from previous passage in 1x MEM with TPCK-treated trypsin (1 µg/mL) in a 500 µL volume. 3. Prepare a single dilution of antibody (0.02 mg/mL for the original passage or higher for all following passages) in 1x MEM with TPCKtreated trypsin in a 250 µL volume. 4. Mix 250 µL of diluted virus with 250 µL of diluted antibody (+antibody) or 250 µL of 1x MEM (no antibody control). 5. Incubate the virus-antibody mixture for 30 min in a 37 °C incubator (with 5% CO 2 ). 6. Aspirate the media using a glass Pasteur pipette and wash the monolayer of cells with 1 mL of 1X PBS. 7. Add 500 µL of the mixtures into the wells and incubate in a 37 °C incubator (with 5% CO 2 ) for 1 h. 8. After 1 h, supplement the wells with 2 mL of 1x MEM with TPCK-treated trypsin (1 µg/mL). 9. Check the cells at 48 h post-infection for signs of cytopathic effect (CPE) on the microscope or perform a hemagglutination assay to detect viral growth
Protocol 2: HI-negative/Neutralization-positive antibodies (

Extraction of Viral RNA and Analysis of HA Sequence Variation
1. Extract the viral RNA from 200 µL of escape mutant virus allantoic fluid with a mono-phasic solution of phenol and guanidine isothiocyanate. CAUTION: Phenol is a volatile liquid reagent that can cause cough, shortness of breath and moderately irritate the skin by contact. 2. Amplify the HA segment from the viral RNA with the use of a reverse transcriptase and gene-specific primers for the influenza A HA segment 27 . NOTE: The universal primers for influenza B viruses described in Table 2 amplify both the HA (~1,800 bp) and the NA (~ 1,500 bp) 28 .
3. Resolve the RT-PCR product in a 1% agarose gel and cut out the correctly sized band (~1,800 bp). 4. Gel extract the PCR product using a silica-membrane based purification procedure and send the cDNA out for sequencing. 5. Identify the amino acid residue required for antibody binding by differentiating the mutations found on putative escape variants and passaged wild-type virus due to either cell culture adaptation or immunological selection. 6. Clone the PCR product containing the wild-type or escape variant HA into a pCAGGs expression vector (NotI and NheI). 7. Binding of the antibody to the escape variant HA can be assessed with one of two options (or both) described below.
Antibody Binding Analyses of Escape Variants
Representative Results
We have previously used variations of this method to generate escape variants to human and murine mAbs induced by the seasonal influenza virus vaccine, H7N9 vaccination, or sequential DNA/recombinant HA protein vaccination 4, 5, 6, 7 . As described above, antibodies were first characterized using the HI and microneutralization assays in order to inform us of which specific protocol to continue with next 4, 5 . Antibodies 07-5D03, 07-5F01, 07-5G01, 07-4B03, 07-4E02 and 07-4D05 were found to have HI and neutralization activities against the avian H7N9 virus (A/Shanghai/1/2013) ( Table 1) , and thus protocol 1 (step 2.1) was utilized. For mAbs with neutralizing that lack HI activity, such as 41-5E04, 045-051310-2B06, 042-100809-2F04 and S6-B01 (Table 1) , protocol 2 (step 2.2) was used to generate escape variants. Escape mutant mapping revealed that many of the antibodies recognize critical residues in distinct locations on the viral HA 4,5 (Figure 4) . While the majority of the HI-positive antibodies have escape mutant residues near previously reported antigenic sites of the H7 HA, the HI-negative antibodies generated escape mutants with point mutations in the stalk region 4, 5 . 
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Discussion
Although the majority of residues identified via escape mutants have been accurate, one of the major caveats of this approach is that point mutations of escape variants may not necessarily map within the molecular footprint of the antibody as determined by structural analyses. This is due to the ability of a mutation at a certain residue to lead to a conformational change distal to the location of the mutated residue, analogous to an allosteric effect. Another limitation is that this methodology can only be implemented for neutralizing antibodies; antibodies that lack in vitro selective pressure will not lead to escape mutants. However, this limitation can be overcome with the use of a panel of escape variants generated by previously characterized neutralizing antibodies. Tan et al. used an escape variant of a neutralizing mAb to the H7N9 virus to map the epitope of a non-neutralizing antibody 7 .
Nonetheless, elucidating the epitopes of antibodies through the generation of escape variants provides a viable alternative to crystallography and cryo-electron microscopy, both of which require an extensive investment of equipment. Other alternatives are to determine the minimal binding region of mAbs using alanine scanning or peptide scanning/truncation mutants. Alanine scanning mutagenesis may require a significant amount of work in generating a large number of variants during screening 29 , while peptide scanning is limited to linear epitopes 30 . The method described in this protocol requires no special equipment or technique and in fact, makes use of existing in vitro neutralization assays modified to generate escape variants of the antibodies of interest.
The protocol for generating escape variants that require multiple passages (e.g., stalk-specific antibodies) is highly dependent on the starting concentration of antibody in passage 0. It is better to err on the side of caution and start at a log to half a log lower than the half maximal inhibitory concentration of an antibody and allow for robust virus growth. The researcher can speculate that a high titer virus culture in the presence of low immunological pressure will have a large genetic variation in the viral population. Escape variants can be selected for by gradually increasing the antibody concentration in the following passages. In the event that the virus growth decreases, the amount of viral supernatant can be increased in the next passage while maintaining the same amount of antibody concentration in the previous passage.
The aim of a majority of universal influenza vaccines is to elicit a robust antibody response towards the stalk region of the HA. The analyses of escape variants to stalk-specific antibodies are important in defining the relationship between influenza virus fitness and immunological pressure. Interestingly, escape mutant viruses resulting from stalk-specific mAbs were all attenuated in vivo in murine LD 50 studies 4 . These studies provide a strong case for stalk-based vaccination platforms. Additionally, this protocol could be used to identify escape mutants to other anti-viral compounds, such as small molecule inhibitors. Finally, this methodology is not limited to influenza virus surface glycoproteins, but may also be more widely applied to determine the epitopes of other viral glycoproteins.
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